Real world outcome of high-risk multiple myeloma: An Indian tertiary care centre experience

Last Updated: Thursday, November 7, 2024

This retrospective study from a tertiary care center in North India examined outcomes of high-risk multiple myeloma (HRMM) patients, finding that autologous stem cell transplant (ASCT) significantly improved overall survival (OS) and progression-free survival (PFS) rates. Patients who received ASCT had a 3-year OS of 74.7% compared to 52.9% without ASCT, highlighting the benefit of aggressive treatment in real-world settings for HRMM.

Clinical Lymphoma, Myeloma & Leukemia

Journal of Patient-Reported Outcomes

Trajectory, interactions, and predictors of higher symptom burden during induction therapy for multiple myeloma

Blood Advances

Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma

Cancer Metastasis Reviews

CAR T-cell therapy to treat multiple myeloma: Current state and future directions

Journal of Cancer Policy

Financial conflicts among physician speakers at the April 12, 2024, Oncology Drug Advisory Meeting: Who decided that MRD can be a novel regulatory endpoint in myeloma?

Cancer Medicine

Comparison of time to next treatment or death between front-line daratumumab, lenalidomide, and dexamethasone (DRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) among transplant-ineligible patients with multiple myeloma

Pharmaceuticals

Unravelling transplant-ineligible newly diagnosed multiple myeloma treatment in real-world practice in Spain: The CARINAE study

Clinical Lymphoma, Myeloma & Leukemia

Real world outcome of high-risk multiple myeloma: An Indian tertiary care centre experience

Annals of Hematology

Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

Clinical Lymphoma, Myeloma & Leukemia

Pomalidomide/daratumumab/dexamethasone in relapsed or refractory multiple myeloma: Final overall survival from MM-014

Frontiers in Immunology

Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4

Multiple Myeloma Resource Center

Real world outcome of high-risk multiple myeloma: An Indian tertiary care centre experience

Journal of Patient-Reported Outcomes

Trajectory, interactions, and predictors of higher symptom burden during induction therapy for multiple myeloma

Blood Advances

Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma

Cancer Metastasis Reviews

CAR T-cell therapy to treat multiple myeloma: Current state and future directions

Journal of Cancer Policy

Financial conflicts among physician speakers at the April 12, 2024, Oncology Drug Advisory Meeting: Who decided that MRD can be a novel regulatory endpoint in myeloma?

Cancer Medicine

Comparison of time to next treatment or death between front-line daratumumab, lenalidomide, and dexamethasone (DRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) among transplant-ineligible patients with multiple myeloma

Pharmaceuticals

Unravelling transplant-ineligible newly diagnosed multiple myeloma treatment in real-world practice in Spain: The CARINAE study

Clinical Lymphoma, Myeloma & Leukemia

Real world outcome of high-risk multiple myeloma: An Indian tertiary care centre experience

Annals of Hematology

Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

Clinical Lymphoma, Myeloma & Leukemia

Pomalidomide/daratumumab/dexamethasone in relapsed or refractory multiple myeloma: Final overall survival from MM-014

Frontiers in Immunology

Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4

Patient Newly Diagnosed With MM and Ineligible for SCT With Relapse on Anti-CD38 and Lenalidomide-Based Therapy

Single Solitary Plasmacytoma to Active Myeloma

A Heavily Treated Relapsed/Refractory Multiple Myeloma Patient on Talquetamab